The PSP pedigree caused by the novel MAPT (E342K) variant have been expanding the mutational spectrum of MAPT. The findings in the present study may be helpful for the development of targeted therapeutic interventions of PSP. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.